Advertisement

Neuropharmacology in the Intensive Care Unit

Published:September 30, 2022DOI:https://doi.org/10.1016/j.ccc.2022.07.007

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Critical Care Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Devlin J.W.
        • Skrobik Y.
        • Gelinas C.
        • et al.
        Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU.
        Crit Care Med. 2018; 46: e825-e873
        • Peng P.W.
        • Sandler A.N.
        A review of the use of fentanyl analgesia in the management of acute pain in adults.
        Anesthesiology. 1999; 90: 576-599
        • Roan J.P.
        • Bajaj N.
        • Davis F.A.
        • et al.
        Opioids and chest wall rigidity during mechanical ventilation.
        Ann Intern Med. 2018; 168: 678
        • Coruh B.
        • Tonelli M.R.
        • Park D.R.
        Fentanyl-induced chest wall rigidity.
        Chest. 2013; 143: 1145-1146
        • Dowell D.
        • Haegerich T.M.
        • Chou R.
        CDC guideline for prescribing opioids for chronic pain - United States, 2016.
        MMWR Recomm Rep. 2016; 65: 1-49
        • Vallner J.J.
        • Stewart J.T.
        • Kotzan J.A.
        • et al.
        Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects.
        J Clin Pharmacol. 1981; 21: 152-156
        • Sarhill N.
        • Walsh D.
        • Nelson K.A.
        Hydromorphone: pharmacology and clinical applications in cancer patients.
        Support Care Cancer. 2001; 9: 84-96
        • Fishman S.M.
        • Wilsey B.
        • Mahajan G.
        • et al.
        Methadone reincarnated: novel clinical applications with related concerns.
        Pain Med. 2002; 3: 339-348
        • Gazelle G.
        • Fine P.G.
        Methadone for pain: No. 75.
        J Palliat Med. 2004; 7: 303-304
        • Attal N.
        • Cruccu G.
        • Baron R.
        • et al.
        EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.
        Eur J Neurol. 2010; 17: 1113-e88
        • Pandey C.K.
        • Raza M.
        • Tripathi M.
        • et al.
        The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barre syndrome patients in the intensive care unit.
        Anesth Analg. 2005; 101 (table of contents): 220-225
        • Girard T.D.
        • Kress J.P.
        • Fuchs B.D.
        • et al.
        Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial.
        Lancet. 2008; 371: 126-134
        • Strom T.
        • Martinussen T.
        • Toft P.
        A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial.
        Lancet. 2010; 375: 475-480
        • Fraser G.L.
        • Devlin J.W.
        • Worby C.P.
        • et al.
        Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials.
        Crit Care Med. 2013; 41: S30-S38
        • Sharshar T.
        • Citerio G.
        • Andrews P.J.
        • et al.
        Neurological examination of critically ill patients: a pragmatic approach. Report of an ESICM expert panel.
        Intensive Care Med. 2014; 40: 484-495
        • Oddo M.
        • Crippa I.A.
        • Mehta S.
        • et al.
        Optimizing sedation in patients with acute brain injury.
        Crit Care. 2016; 20: 128
        • Betjemann J.P.
        • Lowenstein D.H.
        Status epilepticus in adults.
        Lancet Neurol. 2015; 14: 615-624
        • Glauser T.
        • Shinnar S.
        • Gloss D.
        • et al.
        Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society.
        Epilepsy Curr. 2016; 16: 48-61
      1. DIPRIVAN (propofol injection epiLZ. Fresenius Kabi USA, LLC, IL2020
        • Naaz S.
        • Ozair E.
        Dexmedetomidine in current anaesthesia practice- a review.
        J Clin Diagn Res. 2014; 8 (GE01–4)
        • Patanwala A.E.
        • Martin J.R.
        • Erstad B.L.
        Ketamine for analgosedation in the intensive care unit: a systematic review.
        J Intensive Care Med. 2017; 32: 387-395
        • Lippmann M.
        • Appel P.L.
        • Mok M.S.
        • et al.
        Sequential cardiorespiratory patterns of anesthetic induction with ketamine in critically ill patients.
        Crit Care Med. 1983; 11: 730-734
        • Erstad B.L.
        • Patanwala A.E.
        Ketamine for analgosedation in critically ill patients.
        J Crit Care. 2016; 35: 145-149
        • Christ G.
        • Mundigler G.
        • Merhaut C.
        • et al.
        Adverse cardiovascular effects of ketamine infusion in patients with catecholamine-dependent heart failure.
        Anaesth Intensive Care. 1997; 25: 255-259
        • Tobias J.D.
        • Deshpande J.K.
        • Pietsch J.B.
        • et al.
        Pentobarbital sedation for patients in the pediatric intensive care unit.
        South Med J. 1995; 88: 290-294
        • Gagnon D.J.
        • Fontaine G.V.
        • Riker R.R.
        • et al.
        Repurposing valproate, enteral clonidine, and phenobarbital for comfort in adult ICU patients: a literature review with practical considerations.
        Pharmacotherapy. 2017; 37: 1309-1321
        • Sakamoto H.
        • Fukuda S.
        • Minakawa Y.
        • et al.
        Clonidine induces sedation through acting on the perifornical area and the locus coeruleus in rats.
        J Neurosurg Anesthesiol. 2013; 25: 399-407
        • Midazolam injection
        USP [prescribing information]. Hospira, Inc, Lake Zurich, IL2019
        • Lorazepam injection
        USP [prescribing information]. West-Ward Pharmaceuticals Corp, Eatontown, NJ2008
        • Smith Q.R.
        • Rapoport S.I.
        Cerebrovascular permeability coefficients to sodium, potassium, and chloride.
        J Neurochem. 1986; 46: 1732-1742
        • Messeter K.
        • Nordstrom C.H.
        • Sundbarg G.
        • et al.
        Cerebral hemodynamics in patients with acute severe head trauma.
        J Neurosurg. 1986; 64: 231-237
        • Rosner M.J.
        • Coley I.
        Cerebral perfusion pressure: a hemodynamic mechanism of mannitol and the postmannitol hemogram.
        Neurosurgery. 1987; 21: 147-156
        • Garcia-Morales E.J.
        • Cariappa R.
        • Parvin C.A.
        • et al.
        Osmole gap in neurologic-neurosurgical intensive care unit: its normal value, calculation, and relationship with mannitol serum concentrations.
        Crit Care Med. 2004; 32: 986-991
        • Fink M.E.
        Osmotherapy for intracranial hypertension: mannitol versus hypertonic saline.
        Continuum (Minneap Minn). 2012; 18: 640-654
        • Brophy G.M.
        • Human T.
        Pharmacotherapy pearls for emergency neurological life support.
        Neurocrit Care. 2017; 27: 51-73
        • Rangel-Castilla L.
        • Gopinath S.
        • Robertson C.S.
        Management of intracranial hypertension.
        Neurol Clin. 2008; 26 (x): 521-541
        • Strandvik G.F.
        Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure.
        Anaesthesia. 2009; 64: 990-1003
        • Dillon R.C.
        • Merchan C.
        • Altshuler D.
        • et al.
        Incidence of adverse events during peripheral administration of sodium chloride 3.
        J Intensive Care Med. 2018; 33: 48-53
        • Faiver L.
        • Hensler D.
        • Rush S.C.
        • et al.
        Safety and efficacy of 23.4% sodium chloride administered via peripheral venous access for the treatment of cerebral herniation and intracranial pressure elevation.
        Neurocrit Care. 2021; 35: 845-852
        • Meng L.
        • Nguyen C.M.
        • Patel S.
        • et al.
        Association between continuous peripheral i.v. infusion of 3% sodium chloride injection and phlebitis in adults.
        Am J Health Syst Pharm. 2018; 75: 284-291
        • Ennis K.M.
        • Brophy G.M.
        Management of intracranial hypertension: focus on pharmacologic strategies.
        AACN Adv Crit Care. 2011; 22 ([quiz: 83-4]): 177-182
        • Cook A.M.
        • Morgan Jones G.
        • Hawryluk G.W.J.
        • et al.
        Guidelines for the acute treatment of cerebral edema in neurocritical care patients.
        Neurocrit Care. 2020; 32: 647-666
        • Dunn I.F.K.A.
        • Gormley W.B.
        Brain trauma.
        in: Squire L.R. Encyclopedia of neuroscience. Academic Press, Oxford2009: 407-416
        • Huttner H.B.
        • Schellinger P.D.
        • Hartmann M.
        • et al.
        Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates.
        Stroke. 2006; 37: 1465-1470
        • Alotaibi G.S.
        • Wu C.
        • Senthilselvan A.
        • et al.
        Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study.
        Am J Med. 2016; 129: 879.e19-25
        • Shoeb M.
        • Fang M.C.
        Assessing bleeding risk in patients taking anticoagulants.
        J Thromb Thrombolysis. 2013; 35: 312-319
        • Melkonian M.
        • Jarzebowski W.
        • Pautas E.
        • et al.
        Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.
        J Thromb Haemost. 2017; 15: 1500-1510
        • Tulinsky A.
        Molecular interactions of thrombin.
        Semin Thromb Hemost. 1996; 22: 117-124
        • Schindewolf M.
        • Steindl J.
        • Beyer-Westendorf J.
        • et al.
        Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia.
        J Am Coll Cardiol. 2017; 70: 2636-2648
        • Robson R.
        • White H.
        • Aylward P.
        • et al.
        Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
        Clin Pharmacol Ther. 2002; 71: 433-439
        • Reed M.D.
        • Bell D.
        Clinical pharmacology of bivalirudin.
        Pharmacotherapy. 2002; 22: 105S-11S
        • Hirsh J.
        • Fuster V.
        • Ansell J.
        • et al.
        American Heart A, American College of Cardiology f. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.
        Circulation. 2003; 107: 1692-1711
        • Garcia D.A.
        • Baglin T.P.
        • Weitz J.I.
        • et al.
        Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e24S-e43S
        • Cuker A.
        • Arepally G.M.
        • Chong B.H.
        • et al.
        American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
        Blood Adv. 2018; 2: 3360-3392
        • Chan K.E.
        • Edelman E.R.
        • Wenger J.B.
        • et al.
        Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
        Circulation. 2015; 131: 972-979
        • Blech S.
        • Ebner T.
        • Ludwig-Schwellinger E.
        • et al.
        The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
        Drug Metab Dispos. 2008; 36: 386-399
        • Bates S.M.
        • Weitz J.I.
        The mechanism of action of thrombin inhibitors.
        J Invasive Cardiol. 2000; 12: 27F-32F
        • Alban S.
        Pharmacological strategies for inhibition of thrombin activity.
        Curr Pharm Des. 2008; 14: 1152-1175
      2. COUMADIN(R) oral tablets ii, warfarin sodium oral tablets, intravenous injection. Bristol-Myers Squibb Company, Princeton, NJ2010
        • Frontera J.A.
        • Lewin 3rd, J.J.
        • Rabinstein A.A.
        • et al.
        Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine.
        Neurocrit Care. 2016; 24: 6-46
        • Bower M.M.
        • Sweidan A.J.
        • Shafie M.
        • et al.
        Contemporary reversal of oral anticoagulation in intracerebral hemorrhage.
        Stroke. 2019; 50: 529-536
        • Brophy G.M.
        • Human T.
        • Shutter L.
        Emergency neurological life support: pharmacotherapy.
        Neurocrit Care. 2015; 23: S48-S68
        • Writing Group M.
        • January C.T.
        • Wann L.S.
        • et al.
        2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society.
        Heart Rhythm. 2019; 16: e66-e93
        • Tesoro E.P.
        • Brophy G.M.
        Pharmacological management of seizures and status epilepticus in critically ill patients.
        J Pharm Pract. 2010; 23: 441-454
        • Claassen J.
        • Goldstein J.N.
        Emergency neurological life support: status epilepticus.
        Neurocrit Care. 2017; 27: 152-158
        • Brophy G.M.
        • Bell R.
        • Claassen J.
        • et al.
        Guidelines for the evaluation and management of status epilepticus.
        Neurocrit Care. 2012; 17: 3-23
        • Klein P.
        • Diaz A.
        • Gasalla T.
        • et al.
        A review of the pharmacology and clinical efficacy of brivaracetam.
        Clin Pharmacol. 2018; 10: 1-22
        • Ameli P.A.
        • Ammar A.A.
        • Owusu K.A.
        • et al.
        Evaluation and management of seizures and status epilepticus.
        Neurol Clin. 2021; 39: 513-544
        • Nolan J.P.
        • Morley P.T.
        • Vanden Hoek T.L.
        • et al.
        Therapeutic hypothermia after cardiac arrest: an advisory statement by the advanced life support task force of the International Liaison Committee on Resuscitation.
        Circulation. 2003; 108: 118-121
        • Sadaka F.
        • Veremakis C.
        Therapeutic hypothermia for the management of intracranial hypertension in severe traumatic brain injury: a systematic review.
        Brain Inj. 2012; 26: 899-908
        • Lewis S.R.
        • Evans D.J.
        • Butler A.R.
        • et al.
        Hypothermia for traumatic brain injury.
        Cochrane Database Syst Rev. 2017; 9: CD001048
        • Choi H.A.
        • Ko S.B.
        • Presciutti M.
        • et al.
        Prevention of shivering during therapeutic temperature modulation: the Columbia anti-shivering protocol.
        Neurocrit Care. 2011; 14: 389-394
        • Oddo M.
        • Frangos S.
        • Maloney-Wilensky E.
        • et al.
        Effect of shivering on brain tissue oxygenation during induced normothermia in patients with severe brain injury.
        Neurocrit Care. 2010; 12: 10-16
        • Badjatia N.
        • Strongilis E.
        • Gordon E.
        • et al.
        Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale.
        Stroke. 2008; 39: 3242-3247
        • Jain A.
        • Gray M.
        • Slisz S.
        • et al.
        Shivering treatments for targeted temperature management: a review.
        J Neurosci Nurs. 2018; 50: 63-67
        • Bangash M.N.
        • Kong M.L.
        • Pearse R.M.
        Use of inotropes and vasopressor agents in critically ill patients.
        Br J Pharmacol. 2012; 165: 2015-2033
        • Hollenberg S.M.
        Vasoactive drugs in circulatory shock.
        Am J Respir Crit Care Med. 2011; 183: 847-855
        • Rhoney D.
        • Peacock W.F.
        Intravenous therapy for hypertensive emergencies, part 2.
        Am J Health Syst Pharm. 2009; 66: 1448-1457
        • Aggarwal M.
        • Khan I.A.
        Hypertensive crisis: hypertensive emergencies and urgencies.
        Cardiol Clin. 2006; 24: 135-146
        • Awad A.
        • Stüve O.
        Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.
        Ther Adv Neurol Disord. 2009; 2: 50-61
        • Cree B.A.
        • Lamb S.
        • Morgan K.
        • et al.
        An open label study of the effects of rituximab in neuromyelitis optica.
        Neurology. 2005; 64: 1270-1272
        • Ciron J.
        • Audoin B.
        • Bourre B.
        • et al.
        Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
        Rev Neurol (Paris). 2018; 174: 255-264
        • Salzer J.
        • Svenningsson R.
        • Alping P.
        • et al.
        Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy.
        Neurology. 2016; 87: 2074-2081
        • Zebardast N.
        • Patwa H.S.
        • Novella S.P.
        • et al.
        Rituximab in the management of refractory myasthenia gravis.
        Muscle Nerve. 2010; 41: 375-378
        • Sharshar T.
        • Porcher R.
        • Demeret S.
        • et al.
        Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial.
        JAMA Neurol. 2021; 78: 426-433
        • Farrugia M.E.
        • Goodfellow J.A.
        A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature.
        Front Neurol. 2020; 11: 604
        • Goodkin D.E.
        • Rudick R.A.
        • VanderBrug Medendorp S.
        • et al.
        Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.
        Ann Neurol. 1995; 37: 30-40
        • Howard Jr., J.F.
        • Utsugisawa K.
        • Benatar M.
        • et al.
        Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
        Lancet Neurol. 2017; 16: 976-986
        • Villiger P.M.
        • Adler S.
        • Kuchen S.
        • et al.
        Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
        Lancet. 2016; 387: 1921-1927
        • Clerico M.
        • De Mercanti S.F.
        • Signori A.
        • et al.
        Extending the interval of natalizumab dosing: is efficacy preserved?.
        Neurotherapeutics. 2020; 17: 200-207